Belkin Vision CEO, Daria Lemann-Blumenthal with the newly FDA approved Eagle device.

YAVNE, Israel—Belkin Vision, an Israel-based medical device company, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its glaucoma laser, the Eagle device. The device is intended for use in performing selective laser trabeculoplasty (SLT). The Eagle is a state-of-the-art laser device which offers several advantages over traditional treatment options, according to the company. The laser energy is delivered in a non-contact procedure directly through the limbus to the trabecular meshwork without the need for the use of a gonioscopy lens.

In addition, the device automatically defines the target locatio­n then applies the laser treatment sequence while the eye tracker compensates for any eye movement. Belkin Vision CEO, Daria Lemann-Blumenthal commented, “This achievement has been possible thanks to the skill, passion and dedication of our entire team. We believe that this FDA clearance will have a positive impact on the lives of those affected by glaucoma, offering novel treatment methods and renewed hope for the future.”